CARBILEV (carbidopa; levodopa) by Signatur Biosciences is parkinson's disease are related to depletion of dopamine in the corpus striatum. Approved for parkinson's disease. First approved in 2005.
Drug data last refreshed 18h ago
Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease because it does not cross the blood-brain barrier. However, levodopa the metabolic precursor of dopamine, does cross the blood-brain…
Worked on CARBILEV at Signatur Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.